10-Q: Harvard Bioscience Q3 2025: Deep Losses, Debt Woes, Delisting Risk

Harvard Bioscience reports significant Q3 2025 losses, faces substantial doubt about its going concern status, and navigates Nasdaq delisting threats amid ongoing debt refinancing efforts.

Summary

• Net loss for the three months ended September 30, 2025, was $1.2 million, compared to a net loss of $4.8 million for the same period in 2024.
• Net loss for the nine months ended September 30, 2025, was $53.9 million, a significant increase from $12.4 million for the same period in 2024, primarily due to a $48.0 million goodwill impairment charge.
• Revenues decreased by 6.3% to $20.6 million for Q3 2025 and by 9.7% to $62.8 million for the nine months, attributed to softening worldwide demand from academic research institutions and CROs, and the impact of reciprocal tariffs.
• Gross profit decreased by 5.8% for Q3 and 12.3% for the nine months, with gross margin declining to 56.9% for the nine months (from 58.6%).
• The company faces substantial doubt about its ability to continue as a going concern due to its inability to pay debt obligations and fund operations for at least twelve months without refinancing or extending its Credit Agreement.
• The company is at risk of Nasdaq delisting due to non-compliance with the minimum bid price requirement, with an extended compliance deadline of March 30, 2026.
• Material weaknesses in internal control over financial reporting related to the order-to-cash cycle and physical inventory counts persist, and remediation efforts are ongoing through 2025 and 2026.

Sentiment

Score: 2

Explanation: The company faces severe financial distress, including a substantial net loss driven by goodwill impairment, declining revenues, significant debt obligations with a looming maturity, and a 'going concern' warning. The Nasdaq delisting threat and persistent internal control weaknesses further compound the negative outlook, indicating a very high level of risk and operational instability.

Positives

• Net cash provided by operating activities was $6.8 million for the nine months ended September 30, 2025, a significant improvement from net cash used of $0.3 million in the prior year, positively impacted by reductions in accounts receivable ($2.8 million) and inventories ($1.6 million), and $2.2 million in Employee Retention Tax Credit (ERTC) refunds received.
• Gross margin slightly increased to 58.4% in Q3 2025 from 58.1% in Q3 2024, primarily due to a favorable product mix.
• Sales and marketing expenses decreased by $0.9 million (16.4%) in Q3 2025 and $2.7 million (16.0%) for the nine months.
• General and administrative expenses decreased by $0.8 million (17.2%) in Q3 2025 and $3.1 million (18.4%) for the nine months.
• Research and development expenses decreased by $0.5 million (16.9%) in Q3 2025 and $1.5 million (17.8%) for the nine months.
• Amortization of intangible assets decreased by $0.8 million (20.5%) for the nine months.
• Other operating expenses decreased by $0.9 million (63.3%) for the nine months.

Negatives

• Reported a net loss of $53.9 million for the nine months ended September 30, 2025, significantly higher than the $12.4 million loss in the prior year, primarily due to a $48.0 million goodwill impairment charge.
• Revenues decreased by 9.7% for the nine months and 6.3% for the three months, indicating a decline in core business performance due to softening worldwide demand and tariffs.
• Gross profit decreased by $5.1 million (12.3%) for the nine months, and gross margin for the nine months decreased to 56.9% from 58.6%, due to under-absorption of fixed manufacturing overhead, increased purchase price variance, and a higher mix of lower-margin products.
• Operating income (loss) for the nine months was a loss of $50.3 million, compared to a loss of $6.2 million in the prior year.
• The company faces substantial doubt about its ability to continue as a going concern.
• The company is not in compliance with Nasdaq's minimum bid price requirement and faces delisting risk.
• Material weaknesses in internal control over financial reporting persist, leading to a conclusion that disclosure controls and procedures were not effective.
• Total debt outstanding was $34.0 million as of September 30, 2025, with a maturity date of December 22, 2025, and the company is unable to make additional borrowings under its revolving credit facility.
• Interest expense increased to $1.0 million in Q3 2025 (from $0.9 million) and $2.6 million for the nine months (from $2.4 million), due to a higher effective interest rate (11.0% in Q3 2025 vs. 8.7% in Q3 2024).

Risks

• Substantial doubt exists about the company's ability to continue as a going concern due to its inability to pay debt obligations and fund operations for at least twelve months without refinancing or extending debt repayment.
• Failure to accomplish debt refinancing or repayment steps by December 5, 2025, will constitute an event of default under the Credit Agreement, potentially making outstanding amounts immediately due and payable.
• There is no assurance that alternative sources of capital will be available or obtainable on commercially acceptable terms to refinance outstanding indebtedness.
• Risk of Nasdaq delisting if the company fails to regain compliance with the minimum bid price requirement by March 30, 2026, which may require a reverse stock split.
• Delisting from Nasdaq could adversely affect the ability to raise additional financing, investor trading, market price, and liquidity of common stock.
• Material weaknesses in internal control over financial reporting related to the order-to-cash cycle and physical inventory counts persist, which could lead to misstatements in financial reporting.
• Certain future events and circumstances, including further deterioration of the company's stock price, operating results, macroeconomic conditions, and a higher cost of capital, could result in additional goodwill impairment charges.
• Revenue continues to be affected by softening worldwide demand primarily from academic research institutions and CROs, and the impact of reciprocal tariffs.

Future Outlook

The company is actively working to reach a definitive agreement for refinancing or repayment of its Credit Agreement by December 5, 2025. It continues to explore alternative sources of capital, acknowledging the uncertainty regarding their availability and commercially acceptable terms. Remediation efforts for material weaknesses in internal control over financial reporting are expected to continue throughout fiscal year 2025 and during 2026. The company will also assess the impact of recently issued accounting pronouncements on its financial statements.

Management Comments

• "Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report."
• "Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report."
• "We continue to make progress on these steps, and are working actively to reach a definitive agreement that will accomplish one of these outcomes [refinancing or repayment of the Credit Agreement]."
• "We expect to continue our efforts throughout the remainder of fiscal year 2025 and during 2026 [to remediate material weaknesses]."

Industry Context

The company's revenue has been negatively affected by softening worldwide demand, particularly from academic research institutions and contract research organizations (CROs), and the impact of reciprocal tariffs, especially between the United States and China. This indicates a challenging global market environment for life science technologies and products, potentially influenced by funding uncertainties and trade policies.

Corporate Governance

Legal Proceedings

• The company is occasionally subject to claims and lawsuits which typically arise in the normal course of business; management does not believe the outcome will have a material adverse effect.
• An expense of $0.3 million was recorded during the nine months ended September 30, 2024, related to unclaimed property audits, which was completed during the second quarter of fiscal 2024.

Stakeholder Impact

• Shareholders: Significant net losses, goodwill impairment, going concern risk, and Nasdaq delisting threat could severely impact share value and liquidity. A potential reverse stock split may be required.
• Creditors (Lenders): The company is in non-compliance with debt covenants and faces a critical deadline for refinancing or repayment by December 5, 2025. Failure could lead to immediate debt acceleration and foreclosure on collateral. Interest rates on debt have increased.
• Employees: Restructuring expenses and headcount reductions in North America and Europe indicate potential job insecurity. Reduced compensation costs were a factor in lower operating expenses.
• Customers: Softening worldwide demand from academic research institutions and CROs suggests a challenging sales environment.

Next Steps

• Accomplish steps towards refinancing or repayment of the Credit Agreement by December 5, 2025.
• Continue to explore alternative sources of capital for refinancing the outstanding indebtedness.
• Seek stockholder approval for a reverse stock split if necessary to regain Nasdaq compliance by March 30, 2026.
• Continue efforts to remediate material weaknesses in internal control over financial reporting throughout fiscal year 2025 and during 2026.
• Assess the impact of new accounting pronouncements (ASU No. 2023-09, ASU No. 2024-03, ASU 2025-05) on footnote disclosures and consolidated financial statements.

Key Dates

Recommendation

The company faces severe financial distress, evidenced by a substantial net loss driven by a large goodwill impairment, declining revenues, and a 'going concern' warning. Its debt obligations are critical, with a looming refinancing deadline and a history of covenant non-compliance, leading to increased interest rates and a potential default. The Nasdaq delisting threat further exacerbates investment risk by impacting liquidity and access to capital. Persistent material weaknesses in internal controls indicate fundamental operational and reporting issues. Given these compounding negative factors and the high uncertainty, a seasoned investor would likely recommend a strong sell.

Keywords

Harvard Bioscience, HBIO, 10-Q, Q3 2025, financial results, net loss, revenue decline, goodwill impairment, going concern, debt refinancing, Nasdaq delisting, minimum bid price, internal controls, life sciences, research institutions, CROs, tariffs, SOFR, credit agreement